Acalabrutinib is a targeted therapy medication used to treat certain types of blood cancers, specifically chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [1]. It functions as a Bruton's tyrosine kinase (BTK) inhibitor [1].
How does acalabrutinib work?
Acalabrutinib works by blocking the activity of BTK, a protein that plays a crucial role in the survival and proliferation of cancerous B cells [1]. By inhibiting BTK, acalabrutinib helps to reduce the number of these cancer cells [1].
When is acalabrutinib typically prescribed?
Acalabrutinib is approved for the treatment of adult patients with CLL or SLL [1]. It can be used as a first-line treatment or in patients who have previously been treated for these conditions [1].
What is the difference between acalabrutinib and other BTK inhibitors?
Acalabrutinib is a second-generation BTK inhibitor, designed to be more selective for BTK than older drugs like ibrutinib [1]. This increased selectivity may lead to a different side effect profile [1]. Other BTK inhibitors available include ibrutinib, zanubrutinib, and tirabrutinib [2].
What are the potential side effects of acalabrutinib?
Common side effects associated with acalabrutinib can include diarrhea, fatigue, muscle pain, bruising, headache, and anemia [1]. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider [1].
When does acalabrutinib's patent protection expire?
Information regarding specific patent expiry dates for acalabrutinib is available through resources like DrugPatentWatch.com [3]. Patent exclusivity timelines determine when generic or biosimilar versions of a drug may become available [3].
Who manufactures acalabrutinib?
Acalabrutinib is manufactured by AstraZeneca [1].